Stull, DonaldMcBride, DoreenTian, H.Giménez Arnau, Anna MariaMaurer, MarcusMarsland, AlexanderBalp, Maria MagdalenaKhalil, SamGrattan, Clive2017-11-272017-11-272017Stull D, McBride D, Tian H, Gimenez Arnau A, Maurer M, Marsland A. et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticarial. Br J Dermatol. 2017 Oct;177(4):1093-1101. DOI: 10.1111/bjd.154540007-0963http://hdl.handle.net/10230/33338BACKGROUND: Measurement of disease activity guides treatment of chronic spontaneous urticaria (CSU). A weekly Urticaria Activity Score - here, the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7TD ) - measures severity from 0 to 42. Insufficient evidence exists on whether disease activity states, defined by categorical UAS7TD scores, correlate with other patient-reported outcomes and treatment response. OBJECTIVES: To evaluate and compare categorical UAS7TD scores with selected measures of disease-related quality of life and impact. METHODS: Data from three randomized clinical trials of omalizumab in CSU were pooled. Continuous UAS7TD scores were categorized into five disease activity states: urticaria-free, well-controlled, mild, moderate and severe urticaria. Total scores from the Dermatology Life Quality Index; the Chronic Urticaria Quality of Life questionnaire; and questions on sleep and daily activity interference, presence of angioedema and diphenhydramine use were compared within categorized UAS7TD disease-state scores, using anova for analysis at different time points and mixed-effects regressions for analysis of all data pooled. RESULTS: Pooled analyses showed that categorical UAS7TD disease states accurately predicted differences among treated patients with CSU with different levels of disease activity. A consistent pattern existed between categories, with higher-activity disease states associated with significantly higher impact and an increase in angioedema frequency. Results at different treatment time points were consistent. CONCLUSIONS: Categorical UAS7TD disease states can discriminate between measures when considering the impact of urticaria activity. Using five categorical disease states could simplify clinical assessment and monitoring of treatment efficacy.application/pdfeng© 2017 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. This is an open access article under the terms of the https://creativecommons.org/licenses/by-nc-nd/4.0/ , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.Urticària -- Tractamentinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1111/bjd.15454info:eu-repo/semantics/openAccess